Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15134222 | 1.00 | FKBP1A (0.47) | FKBP1AHPGDHTR2CACENPC1 | |
| SCHEMBL31107769 | 1.00 | FKBP1A (0.47) | FKBP1AHPGDHTR2CACENPC1 | |
| SCHEMBL10826818 | 0.93 | ACE (0.46) | FKBP1AHPGDHTR2CACENPC1 | |
| SCHEMBL8426493 | 0.93 | ACE (0.46) | FKBP1AHPGDHTR2CACENPC1 | |
| SCHEMBL7264075 | 0.91 | ACE (0.53) | HPGDHTR2CACENPC1RAB9A | |
| SCHEMBL7264101 | 0.91 | ACE (0.53) | HPGDHTR2CACENPC1RAB9A | |
| SCHEMBL1292045 | 0.89 | HPGD (0.46) | FKBP1AHPGDACEL3MBTL1ATM | |
| SCHEMBL1292041 | 0.89 | HPGD (0.46) | FKBP1AHPGDACEL3MBTL1ATM | |
| SCHEMBL28968201 | 0.89 | HPGD (0.43) | FKBP1AHPGDHTR2CACENPC1 | |
| SCHEMBL15198907 | 0.89 | HPGD (0.46) | FKBP1AHPGDACEL3MBTL1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186270-B1 | CYCLIC UREA COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC (CA) | 2020-02-19 | — | — | EP | disclosed |
| US-10537652-B2 | Cyclic urea compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2020-01-21 | — | — | US | disclosed |
| US-20190151484-A2 | CYCLIC UREA COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2019-05-23 | — | — | US | disclosed |
| US-20190038602-A1 | GRANZYME B INHIBITOR FORMULATIONS AND METHODS FOR THE TREATMENT OF BURNS | VIDA THERAPEUTICS, INC. (CA) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038602-A1 | GRANZYME B INHIBITOR FORMULATIONS AND METHODS FOR THE TREATMENT OF BURNS | GZMB, CTSB, SERPINB1 | FKBP1A 1088/4885HPGD 1614/4885HTR2C 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.